Medpace Holdings, Inc.

NasdaqGS:MEDP Stock Report

Market Cap: US$14.1b

Medpace Holdings Valuation

Is MEDP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MEDP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$624.65
Fair Value
19.8% undervalued intrinsic discount
11
Number of Analysts

Below Fair Value: MEDP ($501.22) is trading below our estimate of fair value ($624.65)

Significantly Below Fair Value: MEDP is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MEDP?

Key metric: As MEDP is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for MEDP. This is calculated by dividing MEDP's market cap by their current earnings.
What is MEDP's PE Ratio?
PE Ratio33.7x
EarningsUS$418.30m
Market CapUS$14.08b

Price to Earnings Ratio vs Peers

How does MEDP's PE Ratio compare to its peers?

The above table shows the PE ratio for MEDP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.5x
ICLR ICON
18x8.81%US$14.3b
ILMN Illumina
11.5x-3.11%US$14.4b
WST West Pharmaceutical Services
38.6x11.62%US$18.8b
WAT Waters
29.8x17.22%US$19.7b
MEDP Medpace Holdings
33.7x8.13%US$14.1b

Price-To-Earnings vs Peers: MEDP is expensive based on its Price-To-Earnings Ratio (33.7x) compared to the peer average (24.5x).

Price to Earnings Ratio vs Industry

How does MEDP's PE Ratio compare vs other companies in the US Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
BNBX Applied DNA Sciences
0.1xn/aUS$5.54m
No more companies available in this PE range
MEDP 33.7xIndustry Avg. 31.7xNo. of Companies5PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: MEDP is expensive based on its Price-To-Earnings Ratio (33.7x) compared to the US Life Sciences industry average (31.7x).

Price to Earnings Ratio vs Fair Ratio

What is MEDP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MEDP PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio33.7x
Fair PE Ratio25.2x

Price-To-Earnings vs Fair Ratio: MEDP is expensive based on its Price-To-Earnings Ratio (33.7x) compared to the estimated Fair Price-To-Earnings Ratio (25.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MEDP forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$501.22
US$428.00
-14.61%
15.31%US$510.00US$305.00n/a11
Oct ’26US$543.90
US$427.09
-21.48%
14.91%US$510.00US$305.00n/a11
Sep ’26US$475.51
US$410.27
-13.72%
15.65%US$510.00US$305.00n/a11
Aug ’26US$423.09
US$410.27
-3.03%
15.65%US$510.00US$305.00n/a11
Jul ’26US$321.07
US$300.28
-6.48%
6.30%US$342.00US$270.00n/a12
Jun ’26US$294.90
US$300.30
+1.83%
6.58%US$342.00US$270.00n/a11
May ’26US$302.25
US$300.30
-0.64%
6.58%US$342.00US$270.00n/a11
Apr ’26US$297.73
US$341.85
+14.82%
10.55%US$404.00US$296.00n/a11
Mar ’26US$327.32
US$344.83
+5.35%
10.98%US$404.00US$296.00n/a10
Feb ’26US$349.15
US$343.83
-1.52%
10.13%US$400.00US$296.00n/a10
Jan ’26US$332.23
US$347.92
+4.72%
8.99%US$400.00US$296.00n/a10
Dec ’25US$340.63
US$347.92
+2.14%
8.99%US$400.00US$296.00n/a10
Nov ’25US$319.56
US$349.32
+9.31%
9.71%US$404.00US$296.00n/a10
Oct ’25US$333.45
US$380.12
+14.00%
12.69%US$435.00US$296.00US$543.9010
Sep ’25US$355.27
US$395.82
+11.41%
12.09%US$435.00US$296.00US$475.5110
Aug ’25US$385.16
US$395.82
+2.77%
12.09%US$435.00US$296.00US$423.0910
Jul ’25US$407.24
US$429.04
+5.35%
12.14%US$480.00US$296.00US$321.079
Jun ’25US$386.34
US$428.25
+10.85%
12.87%US$480.00US$296.00US$294.908
May ’25US$397.86
US$425.47
+6.94%
13.69%US$480.00US$296.00US$302.257
Apr ’25US$397.99
US$389.50
-2.13%
18.62%US$480.00US$261.00US$297.736
Mar ’25US$404.24
US$382.80
-5.30%
19.20%US$453.00US$261.00US$327.325
Feb ’25US$295.16
US$283.20
-4.05%
8.85%US$312.00US$239.00US$349.155
Jan ’25US$306.53
US$281.20
-8.26%
8.18%US$302.00US$239.00US$332.235
Dec ’24US$275.41
US$278.60
+1.16%
7.60%US$302.00US$239.00US$340.635
Nov ’24US$251.61
US$278.60
+10.73%
7.60%US$302.00US$239.00US$319.565
Oct ’24US$242.13
US$259.00
+6.97%
6.41%US$273.00US$227.00US$333.455
US$428
Fair Value
17.1% overvalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/13 18:43
End of Day Share Price 2025/10/10 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medpace Holdings, Inc. is covered by 18 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eric ColdwellBaird
Luke SergottBarclays
Justin BowersDeutsche Bank